Medesis Pharma lists on Euronext Growth Paris

Jean-Claude Maurel , CEO and Founder of Medesis Pharma, opens the trading day in Paris.

Medesis Pharma S.A. is specialized in the research and development, based on a breakthrough technology (AONYS®) for the delivery of therapeutic molecules, of drugs to treat diseases for which there is no effective treatment.
The company's portfolio includes two candidates in the fields of neurodegenerative diseases (Alzheimer's disease and Huntington's disease), two candidates for antiviral treatments to respond to the health emergency towards the treatment of COVID-19 at different stages (one for hospitalized patients in acute respiratory distress, and another for early treatment in urban medicine), and 2 candidates to treat contaminated populations after a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).